GlobeNewswire
Register
Sign In
English
Français
Contact Us
Global Distribution
Newswire Services
Regulatory Filings
Media Partners
About this file
LDL-C Percent Change From Baseline to Week 6 Endpoint
64% Reduction in LDL-C
Format
PNG
Source
Esperion Therapeutics, Inc.
Downloads
Original
Large
Medium
Small
ASSOCIATED PRESS RELEASE
Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin
Published
August 08, 2017 07:30 ET
Ok